期刊文献+

冠心病患者支架植入术后氯吡格雷与不同质子泵抑制剂联合治疗的疗效比较 被引量:8

Therapeutic effect of combined clopidogrel and proton pump inhibitors in patients with coronary heart disease after stent implantation
原文传递
导出
摘要 目的探讨不同质子泵抑制剂对氯吡格雷抗血小板作用的影响。方法286例在我院实施冠状动脉支架植入术的患者随机分为奥美拉唑40mg/d+氯吡格雷75mg/d组(146例)和泮托拉唑40mg/d+氯吡格雷75mg/d组(140例),连续用药30d,观察主要不良心脑血管事件。结果奥美拉唑组心性死亡、非致死性急性心肌梗死、紧急靶血管血运重建、脑卒中发生率分别为1.37%、2.05%、3.42%、0.68%;泮托拉唑组分别为0.71%、2.85%、2.85%、0.71%,两组无统计学差异(P>0.05)。奥美拉唑组主要不良心脑血管事件、急性亚急性血栓形成发生率分别为7.53%、1.37%,泮托拉唑组分别为7.14%、0.71%,两组亦无统计学差异(P>0.05)。两组出血事件发生率分别为9(6.16%)和9(6.42%),差异无统计学意义(P=0.926)。结论冠心病患者支架植入术后采用氯吡格雷联合奥美拉唑或泮托拉唑治疗的近期疗效相近。 Objective To study the effect of different proton pump inhibitors on omeprazole resistant platelets.Methods A total of 286 patients admitted to our hospital after coronary stent implantation were randomly divided into omeprazole(40mg/d)+ clopidogrel group(n=146)and pantoprazole(40mg/d)+ clopidogrel(75mg/d)group(n=140).Adverse cardiac and cerebral vascular events(MACCE)were observed for 30 days.Results The rates of death due to cardiac events,non-fetal acute infarction,acute target vascular supply reconstruction,and cerebral apoplexy were 1.37%,2.05%,3.42%,and 0.68% respectively in omeprazole+ clopidogrel group,and were 0.71%,2.85%,2.85%,and 0.71% respectively in pantoprazole + clopidogrel group(P0.05).The rates of adverse cardiac and cerebral events and acute or subacute thrombosis were 7.53% and 1.37% respectively in omeprazole+ clopidogrel group and were 7.14% and 0.71% respectively in pantoprazole + clopidogrel group(P0.05).The rates of bleeding were 6.16% and 6.42% respectively in the two groups.Conclusion The short-term therapeutic effects of omeprazole(40mg/d)combined with clopidogrel and pantoprazole combined with clopidogrel are similar in patients with coronary heart disease after coronary stent implantation.
出处 《军医进修学院学报》 CAS 2010年第6期535-537,共3页 Academic Journal of Pla Postgraduate Medical School
基金 全军医药卫生科研基金课题(07BJZ01)~~
关键词 血管成形术 经腔 经皮冠状动脉 氯吡格雷 质子泵抑制剂 Angioplasty Transluminal Percutaneous Coronary Clopidogrel Proton Pump Inhibitors
  • 相关文献

参考文献9

  • 1Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel [J] .CMAJ, 2009, 180 (7): 713-718.
  • 2Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome [ J ] . JAMA, 2009, 301 ( 9 ) : 937-944.
  • 3Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel [ J ] . Thromb Haemost, 2009, 101 (4) : 714-719.
  • 4韩雅玲,王耿,荆全民,王守力,王祖禄,王冬梅,马颖艳,栾波.急性冠状动脉综合征介入治疗4670例近期疗效的评价[J].中华医学杂志,2005,85(15):1040-1044. 被引量:45
  • 5Mehta SR, Yusuf S, Peters R J, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention : the PCI-CURE study [ J ] . Lancet, 2001, 358 (9281) : 527-533.
  • 6Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin : meta-analysis [ J ] . BMJ, 2000, 321 ( 7270 ): 1183-1187.
  • 7O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacody- namic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor : an analysis of two randomised trials [ J ] . Lancet, 2009, 374 ( 9694 ) : 989-997.
  • 8O'Donoghue M, Antman EM, Braunwald E, et al. The efficacy and safety of prasugrel with and without a glycoprotein Ⅱb/Ⅲa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention : a TRITON-TIMI 38(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis [ J ] . J Am Coil Cardiol, 2009, 54 ( 8 ) : 678-685.
  • 9Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrd [ J ] . Thromb Haemost, 2000, 84 (5) : 891.

二级参考文献16

  • 1Pate GE, Humphries KH, Izadnegahdar M, et al. Population rates of invasive cardiac procedures in British Columbia, 1995 to 2001. Can J Cardiol, 2004,20:712-716.
  • 2Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee on Management Acute Myocardial Infarction). Circulation,1999,100:1016-1030.
  • 3Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol, 2000,36:970-1062.
  • 4Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol, 2002,40:1366-1374.
  • 5Ryan TJ, Faxon DP, Gunnar RM, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol, 1988,12:529-545.
  • 6Qiao JH, Fishbein MC. The severity of coronary atherosclerosis at sites of plaque rupture with occlusive thrombosis. J Am Coll Cardiol, 1991,17:1138-1142.
  • 7Ottervanger JP, Armstrong P, Barnathan ES, et al. Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J, 2004, 25:1494-1501.
  • 8Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 2003,361:13-20.
  • 9Al Suwaidi J, Holmes DR Jr, Salam AM, et al. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J, 2004,147:815-822.
  • 10Yip HK, Wu CJ, Yang CH, et al. Delayed post-myocardial infarction invasive measures, helpful or harmful? A subgroup analysis. Chest, 2004,126:38-46.

共引文献44

同被引文献42

  • 1蔡连华.质子泵抑制剂对药物代谢酶CYP1A2、NAT2的影响分析[J].中国现代药物应用,2007,1(10):33-34. 被引量:3
  • 2张煜.新型第3质子泵抑制剂——泮立苏[J].中国社区医师,2005,21(21):15-15. 被引量:5
  • 3王婷婷,李柯,魏蕾.血管扩张刺激磷蛋白在细胞骨架调节中的作用[J].生理科学进展,2006,37(1):27-30. 被引量:9
  • 4Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump in- hibitors following acute coronary syndrome. JAMA, 2009,301 : 937-944.
  • 5Juurlink DN, Gomes T, Ko DT, et al. Apopulation-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009,180:713-718.
  • 6Kim KA, Park PW., Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther, 2008,84:236-242.
  • 7Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol, 2001,13(5): 611-616.
  • 8Li XQ,Andersson TB,Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos, 2004, 32: 821- 827.
  • 9Steven PD, Tracy EM,Danielle MB, et al. Baseline proton pump inhibitor use is assocated with increased cardiovascular events with and without the use of elopidogrel in the CREDO trial. Circulation, 2008,118:815A.
  • 10O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet, 2009,374 : 989-997.

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部